Annual general meeting

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Retrieved on: 
Friday, April 5, 2024
Head, Algorithm, Immunotherapy, University, Neoplasm, PM, Vaccine, Analysis, Navigation, Mutation, Thermo Fisher Scientific, Cancer, Unprecedented, Glioblastoma, Result, Risk, Research, Tumor microenvironment, Antibody, Security (finance), Personalized medicine, PST, Proteomics, AACR, Pancreatic cancer, Ultrahigh, Conversation, Annual general meeting, AQUA, Lung cancer, University of Queensland, MIT, Titan Mare Explorer, Medical imaging

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.

Key Points: 
  • MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.
  • Industry-leading capabilities of the company’s spatial biology platforms will be presented during Akoya’s Spotlight Theater, titled “Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale” on Monday, April 8 at 3 PM (PST).
  • Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform.
  • PhenoImager HT 2.0: Features targeted PhenoCode Signature Panels and onboard spectral unmixing, simplifying biomarker development and validation workflows for large scale studies.

Whitestone REIT Files Definitive Proxy Materials and Mails Letter to Shareholders

Retrieved on: 
Friday, April 5, 2024
Failure, Letter, Growth, WSR, Trustee, Total shareholder return, Cedar Realty Trust, PECO, RMS, Sale, Security (finance), NOI, Morale, REIT, High, Investment, FFO, IVT, Annual general meeting, Management

HOUSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that it has filed its definitive proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its 2024 Annual Meeting of Stockholders scheduled to be held on May 14th, 2024. Shareholders of record as of February 21, 2024, will be entitled to vote at the meeting.

Key Points: 
  • In conjunction with the definitive proxy filing, Whitestone has mailed a letter to the Company’s shareholders.
  • Under our new plan, we have paved the path forward to maximize value for Whitestone shareholders.
  • Voting for each of Whitestone’s nominees on the WHITE proxy card is in the best interests of all shareholders.
  • As previously mentioned, Erez’s mission seems to be to establish Bruce Schanzer’s credibility in the REIT activism arena and use Whitestone REIT as proof-of-concept.

GOGL – Notice of 2024 Annual General Meeting

Retrieved on: 
Friday, April 5, 2024
Disclosure, Annual general meeting, Security (finance), Financial statement

Golden Ocean Group Limited (the “Company”) announces that its 2024 Annual General Meeting will be held on April 29, 2024.

Key Points: 
  • Golden Ocean Group Limited (the “Company”) announces that its 2024 Annual General Meeting will be held on April 29, 2024.
  • A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements on Form 20-F for 2023 can be found on our website at www.goldenocean.bm and in the links below.
  • This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Trisura Group Announces Changes to its Board of Directors

Retrieved on: 
Thursday, April 4, 2024
Risk management, General counsel, Intact Financial, Power Corporation of Canada, TSX, Annual general meeting, Investment, Retirement, Corporate development, Corporation

TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU) today announced the appointment of Lilia Sham to its Board of Directors and the retirement of Greg Morrison.

Key Points: 
  • TORONTO, April 04, 2024 (GLOBE NEWSWIRE) -- Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU) today announced the appointment of Lilia Sham to its Board of Directors and the retirement of Greg Morrison.
  • In addition, Trisura today announced that Sacha Haque is expected to stand for election to the Board of Directors at this year’s Annual General Meeting.
  • “We are pleased to welcome Lilia Sham to our Board of Directors and look forward to the expected election of Sacha Haque to our Board of Directors at our Annual General Meeting on June 3, 2024.
  • We look forward to the guidance Ms. Sham and Ms. Haque will provide as Trisura continues to execute its strategy.” said George Myhal, Chair, Board of Directors, Trisura Group Ltd.
    Mr. Myhal continued, “We would also like to thank Greg Morrison for his many contributions to Trisura.

Badger Infrastructure Solutions Ltd. Confirms Release Date for Q1 2024 Results and Filing of Management Information Circular in Connection With 2024 Annual Meeting of Shareholders

Retrieved on: 
Thursday, April 4, 2024
Annual, Webcast, Circular, TSX, Annual general meeting, Management

CALGARY, Alberta, April 04, 2024 (GLOBE NEWSWIRE) -- Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) (TSX:BDGI) confirms the release date for its Q1 2024 results and the filing of the management information circular prepared in connection with its 2024 annual meeting of shareholders (the “Annual Meeting”) scheduled to be held on May 2, 2024.

Key Points: 
  • CALGARY, Alberta, April 04, 2024 (GLOBE NEWSWIRE) -- Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) (TSX:BDGI) confirms the release date for its Q1 2024 results and the filing of the management information circular prepared in connection with its 2024 annual meeting of shareholders (the “Annual Meeting”) scheduled to be held on May 2, 2024.
  • Badger expects to release its 2024 first quarter results on Wednesday, May 1, 2024, after markets close.
  • Badger has filed the Management Information Circular prepared in connection with the Annual Meeting being held on Thursday, May 2, 2024, at 10:00 a.m. MT.
  • Following the formal portion of the Annual Meeting, a presentation will be given by Rob Blackadar, President & Chief Executive Officer of Badger.

O-I Glass Appoints Gordon Hardie as Chief Executive Officer

Retrieved on: 
Thursday, April 4, 2024
PepsiCo, Culture, Glass, Sherwin-Williams, Fortune Brands, Bunge Limited, Aramark, Chairperson, Consumer, Food, Security (finance), Pleasure, Primo Water, Cineworld, Annual general meeting, Management

PERRYSBURG, Ohio, April 04, 2024 (GLOBE NEWSWIRE) --  O-I Glass, Inc. (NYSE: O-I) (the “Company” or “O-I”) today announced that its Board of Directors (the “Board”) has appointed Gordon J. Hardie, current O-I Board member, as the Company’s next Chief Executive Officer, effective the later of May 15, 2024 or the date Gordon is issued his work-authorized U.S. visa. Gordon will also continue as a member of O-I’s Board, where he has served since 2015. He succeeds Andres Lopez, who previously announced his intention to retire.

Key Points: 
  • PERRYSBURG, Ohio, April 04, 2024 (GLOBE NEWSWIRE) --  O-I Glass, Inc. (NYSE: O-I) (the “Company” or “O-I”) today announced that its Board of Directors (the “Board”) has appointed Gordon J. Hardie, current O-I Board member, as the Company’s next Chief Executive Officer, effective the later of May 15, 2024 or the date Gordon is issued his work-authorized U.S. visa.
  • Gordon is a seasoned executive who brings over 35 years of leadership and operational expertise, including overseeing transformations at global companies to achieve industry-leading positions.
  • “Gordon is a proven leader with extensive experience in the packaged food and beverage industry, bringing valuable customer perspective.
  • Eric is an experienced executive having previously served as Chairman, President and Chief Executive Officer of Aramark, a leading global provider of food, facilities and uniform services, until he retired from his roles in 2019.

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, April 4, 2024
Toxicity, B cell, Conditional sentence, SOC, Survival, Survival rate, Chemoradiotherapy, Patient, Neoplasm, Tumor microenvironment, Standard of care, Doctor of Philosophy, Lymphocyte, Pancreatic cancer, Therapy, Cytokine, Injection, Pancreatitis, CD8, SITC, Recurrence, Valaciclovir, FDA, Annual general meeting, CADL, Food, Pharmaceutical industry

At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Key Points: 
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.
  • Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data shown in this randomized clinical trial.
  • Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Thursday, April 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Poster, Annual general meeting, KRYS, Interleukin, AACR

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleukin-2 (IL-2), the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research (AACR) 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.

Key Points: 
  • PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleukin-2 (IL-2), the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research (AACR) 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.
  • Poster presentation details are as follows:
    The poster will be available to conference attendees.
  • Following the presentation, the poster will also be available to view online on the Investor section of the Company’s website .

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Thursday, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.